The dimensions of clinical and cognitive change in schizophrenia: evidence for independence of improvements

[1]  R. Keefe.  THE COGNITIVE EFFECTS OF RISPERIDONE, OLANZAPINE AND QUETIAPINE IN PATIENTS WITH FIRST EPISODE PSYCHOSIS , 2008, Schizophrenia Research.

[2]  Michael F. Green,et al.  Baseline Neurocognitive Deficits in the CATIE Schizophrenia Trial , 2006, Neuropsychopharmacology.

[3]  Herbert Y Meltzer,et al.  A meta-analysis of neuropsychological change to clozapine, olanzapine, quetiapine, and risperidone in schizophrenia. , 2005, The international journal of neuropsychopharmacology.

[4]  Philip D. Harvey,et al.  Ziprasidone: efficacy, tolerability, and emerging data on wide-ranging effectiveness , 2005, Expert opinion on pharmacotherapy.

[5]  Michael F. Green,et al.  Longitudinal studies of cognition and functional outcome in schizophrenia: implications for MATRICS , 2004, Schizophrenia Research.

[6]  J. Gold.  Cognitive deficits as treatment targets in schizophrenia , 2004, Schizophrenia Research.

[7]  S. McGurk,et al.  Cognitive functioning, symptoms, and work in supported employment: a review and heuristic model , 2004, Schizophrenia Research.

[8]  P. Weiden,et al.  Randomized, controlled, double-blind multicenter comparison of the efficacy and tolerability of ziprasidone and olanzapine in acutely ill inpatients with schizophrenia or schizoaffective disorder. , 2004, The American journal of psychiatry.

[9]  Susan Cooley,et al.  Cognitive enhancement therapy for schizophrenia: effects of a 2-year randomized trial on cognition and behavior. , 2004, Archives of general psychiatry.

[10]  Luke Clark,et al.  Modafinil Improves Cognition and Attentional Set Shifting in Patients with Chronic Schizophrenia , 2004, Neuropsychopharmacology.

[11]  J. Lieberman,et al.  Comparative effect of atypical and conventional antipsychotic drugs on neurocognition in first-episode psychosis: a randomized, double-blind trial of olanzapine versus low doses of haloperidol. , 2004, The American journal of psychiatry.

[12]  Michael F. Green,et al.  Cognitive functioning in schizophrenia: a consensus statement on its role in the definition and evaluation of effective treatments for the illness. , 2004, The Journal of clinical psychiatry.

[13]  Philip D. Harvey,et al.  Randomized, controlled, double-blind, multicenter comparison of the cognitive effects of ziprasidone versus olanzapine in acutely ill inpatients with schizophrenia or schizoaffective disorder , 2004, Psychopharmacology.

[14]  Steven G Potkin,et al.  Improvement in cognitive function following a switch to ziprasidone from conventional antipsychotics, olanzapine, or risperidone in outpatients with schizophrenia , 2004, Schizophrenia Research.

[15]  Philip D. Harvey,et al.  The relationship of neuropsychological test performance with the PANSS in antipsychotic naı̈ve, first-episode psychosis patients , 2003, Schizophrenia Research.

[16]  S. Potkin,et al.  Effectiveness of switching to ziprasidone for stable but symptomatic outpatients with schizophrenia. , 2003, The Journal of clinical psychiatry.

[17]  Michael F. Green,et al.  Changes in cognitive functioning with risperidone and olanzapine treatment: a large-scale, double-blind, randomized study , 2003, Psychopharmacology.

[18]  S. Hyman,et al.  What Are the Right Targets for Psychopharmacology? , 2003, Science.

[19]  Alexander L. Miller,et al.  Does cognitive function improve with quetiapine in comparison to haloperidol? , 2002, Schizophrenia Research.

[20]  R. Gur,et al.  Approaches to Cognitive Remediation of Neuropsychological Deficits in Schizophrenia: A Review and Meta-Analysis , 2001, Neuropsychology Review.

[21]  Philip D. Harvey,et al.  Cognition in schizophrenia , 2001, Current psychiatry reports.

[22]  T. Laughren.  A regulatory perspective on psychiatric syndromes in Alzheimer disease. , 2001, The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.

[23]  Philip D. Harvey,et al.  Guanfacine Treatment of Cognitive Impairment in Schizophrenia , 2001, Neuropsychopharmacology.

[24]  Philip D. Harvey,et al.  The convergence of neuropsychological testing and clinical ratings of cognitive impairment in patients with schizophrenia. , 2001, Comprehensive psychiatry.

[25]  R. Conley,et al.  A randomized double-blind study of risperidone and olanzapine in the treatment of schizophrenia or schizoaffective disorder. , 2001, The American journal of psychiatry.

[26]  Philip D. Harvey,et al.  Practice-related improvement in information processing with novel antipsychotic treatment , 2000, Schizophrenia Research.

[27]  B. Wexler,et al.  California Verbal Learning Test practice effects in a schizophrenia sample , 1999, Schizophrenia Research.

[28]  Alexander L. Miller,et al.  The functional significance of symptomatology and cognitive function in schizophrenia , 1997, Schizophrenia Research.

[29]  C. Beasley,et al.  Olanzapine versus haloperidol: acute phase results of the international double-blind olanzapine trial , 1997, European Neuropsychopharmacology.

[30]  Philip D. Harvey,et al.  Cognitive impairment and negative symptoms in geriatric chronic schizophrenic patients: a follow-up study , 1996, Schizophrenia Research.

[31]  Philip D. Harvey,et al.  Empirical evaluation of the factorial structure of clinical symptoms in schizophrenia: Effects of typical neuroleptics on the brief psychiatric rating scale , 1996, Biological Psychiatry.

[32]  Michael F. Green,et al.  What are the functional consequences of neurocognitive deficits in schizophrenia? , 1996, The American journal of psychiatry.

[33]  M. Tohen,et al.  One hundred years of schizophrenia: a meta-analysis of the outcome literature. , 1994 .

[34]  C. Waternaux,et al.  One hundred years of schizophrenia: A meta-analysis of the outcome literature , 1993, Schizophrenia Research.

[35]  Jean Addington,et al.  Cognitive functioning and positive and negative symptoms in schizophrenia , 1991, Schizophrenia Research.

[36]  Barbara A. Cornblatt,et al.  The continuous performance test, identical pairs version: II. Contrasting attentional profiles in schizophrenic and depressed patients , 1989, Psychiatry Research.

[37]  R. Tandon,et al.  Positive and negative syndromes in schizophrenia. , 1989, The American journal of psychiatry.

[38]  T. Oltmanns,et al.  Schizophrenic performance when distractors are present: attentional deficit or differential task difficulty? , 1975, Journal of abnormal psychology.

[39]  B. Wexler,et al.  Cognitive remediation and vocational rehabilitation for schizophrenia. , 2005, Schizophrenia bulletin.

[40]  S. McGurk,et al.  Cognitive training and supported employment for persons with severe mental illness: one-year results from a randomized controlled trial. , 2005, Schizophrenia bulletin.

[41]  Philip D. Harvey,et al.  Stability of cognitive performance in older patients with schizophrenia: an 8-week test-retest study. , 2005, The American journal of psychiatry.

[42]  S. Hyman,et al.  Medicine. What are the right targets for psychopharmacology? , 2003, Science.

[43]  Philip D. Harvey,et al.  Empirical assessment of the factorial structure of clinical symptoms in schizophrenia. A multisite, multimodel evaluation of the factorial structure of the Positive and Negative Syndrome Scale. The PANSS Study Group. , 1997, Psychopathology.

[44]  Robert K. Heaton,et al.  Wisconsin Card Sorting Test Manual – Revised and Expanded , 1993 .

[45]  R. Reitan,et al.  The Halstead-Reitan neuropsychological test battery: Theory and clinical interpretation , 1993 .

[46]  M. Schlossberg.  The Halstead-Reitan Neuropsychological Test Battery: Theory and Clinical Interpretation. , 1986 .